

IFW

OIPE IAP48
 AUG 25 2006
 PATENT & TRADEMARK OFFICE

§ § § § § § § § § §

Group Art Unit: 1618

Attorney
Docket: 29195

Attorney
Docket: 29195

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir:


Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan
Martin D. Moynihan
Registration No. 40,338

Dated: August 15, 2006



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/525,951
				Filing Date	February 28, 2005
				First Named Inventor	Doron SHABAT et al
				Art Unit	1618
				Examiner Name	VU, JAKE MINH
Sheet	1	of	3	Attorney Docket Number	29195
U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-4,694,064	09-15-1987	Tomalia et al.	
	2	US-4,938,885	03-3-1990	Migdal	
	3	US-5,098,475	03-24-1992	Winnik et al.	
	4	US-5,256,193	10-26-1993	Winnik et al.	
	5	US-5,256,516	10-26-1993	Winnik et al.	
	6	US-5,266,106	11-30-2006	97 Winink et al.	
	7	US-5,332,640	07-26-1994	Duff et al.	
	8	US-5,393,795	02-28-1995	Hedstrand et al.	
	9	US-5,393,797	02-28-1995	Hedstrand et al.	
	10	US-5,648,186	07-15-1997	Daroux et al.	
	11	US-5,661,025	08-26-1997	Szoka Jr. et al.	
	12	US-5,714,166	03-3-1998	Tomalia et al.	
	13	US-5,736,346	07-7-1998	Tezón et al.	
	14	US-5,788,989	04-4-1999	Jansen et al.	
	15	US-5,902,863	05-11-1999	Dvornic et al.	
	16	US-5,938,934	08-17-1999	Balogh et al.	
	17	US-5,990,089	11-23-1999	Szoka Jr. et al.	
	18	US-6,068,835	05-30-2000	Franzke et al.	
	19	US-6,083,708	04-4-2000	Singh et al.	
	20	US-6,113,946	05-5-2000	Szoka Jr. et al.	
	21	US-6,184,313	06-6-2001	Roovers et al.	
	22	US-6,187,897	02-13-2001	Kawashima et al.	
	23	US-6,224,898	01-1-2001	Balogh et al.	
	24	US-6,228,978	08-8-2001	Agarwal et al.	
	25	US-6,288,253	09-11-2001	Manzer et al.	
	26	US-6,306,991	10-23-2001	Fischer et al.	
	27	US-6,312,809	06-6-2001	Crooks et al.	
	28	US-6,365,562	02-2-2002	Fischer et al.	
	29	US-6,395,257	05-28-2002	Achilefu et al.	
	30	US-6,410,680	06-25-2002	Kubota et al.	
	31	US-6,452,053	09-19-2002	Fischer et al.	
	32	US-6,464,971	10-15-2002	Matthews et al.	
	33	US-6,506,218	01-14-2003	Fischer et al.	
	34	US-6,545,101	08-8-2003	Agarwal et al.	
	35	US-6,570,031	05-27-2003	Becke et al.	
	36	US-6,579,906	06-17-2003	Cooper et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	37	PCT WO 02/083180	10-24-2002	De Groot et al.		
Examiner Signature				Date Considered		



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (1885-0185), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/525,951
				Filing Date	February 28, 2005
				First Named Inventor	Doron SHABAT et al
				Group Art Unit	1618
				Examiner Name	VU, JAKE MINH
Sheet	2	of	3	Attorney Docket Number	29195
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	38	Forney et al. "Selction of Amidases With Novel Substrate Specificities From Penicillin Amidase of Eshcerichia Coli", Applied and Environmental Microbiology, 55(10): 2550-2555, 1989.			
	39	Hande "Etoposide: Four Decades of Development of A Topoisomerase II Inhibitor", European Journal of Cancer, 34(10): 1514-1521, 1998.			
	40	Hawker et al. "Preparation of Polymers With Controlled Moelcular Architecture. A New Convergent Approach to Dendritic Macromolecules", Journal of the American Chemical Society, 112: 7638-7647, 1990.			
	41	Ihre et al. "Polyester Dendritic Systems for Drug Delivery Applications: Design, Synthesis, and Characterization", Bioconjugate Chemistry, 13: 443-452, 2002.			
	42	Kim et al. "Applications of Dendrimers in Bio-Organic Chemistry", Current Opinion in Chemical Biology, 2: 733-742, 1998.			
	43	Klajnert et al. "Dendrimers: Properties and Applications", Acta Biochimica Polonica, 48(1): 199-208, 2001.			
	44	Kojima et al. "Synthesis of Polyamidoamine Dendrimers Having Poly(Ethylene Glycol) Grafts and Their Ability to Encapsulate Anticancer Drugs", Bioconjugate Chemistry, 11: 910-917, 2000.			
	45	Leu et al. "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)", Journal of Medicinal Chemistry, 42: 3623-3628, 1999.			
	46	Madec-Lougerstay et al. "Synthesis of Self-Immolative Glucuronide Spacers Based on Aminomethylcarbamate. Application to 5-Fluorouracil Prodrugs for Antibody-Directed Enzyme Prodrug Therapy", Journal of the Chemical Society, Perkin Transactions, 1: 1369-1375, 1999.			
	47	Maeda et al. "Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review", Journal of Controlled Release, 65: 271-284, 2000.			
	48	Margolin et al. "Substrate Specificity of Penicillin Amidase From E. Coli", Biochimica et Biophysica Acta, 616(2): 283-289, 1980.			
	49	Padilla De Jesús et al. "Polyester Dendritic Systems for Drug Delivery Applications: In Vitro and In Vivo Evaluation", Bioconjugate Chemistry, 13: 453-461, 2002.			
	50	Patri et al. "Dendritic Polymer Macromolecular Carriers for Drug Delivery", Current Opinion in Chemical Biology, 6: 466-471, 2002.			
	51	Satchi et al. "PDEPT: Polymer-Directed Enzyme Prodrug Therapy. I. HPMa Copolymer-Cathepsin B and PK1 as A Model Combination", British Journal of Cancer, 85(7): 1070-1076, 2001.			
Signature					
				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/525,951
Filing Date	February 28, 2005
First Named Inventor	Doron SHABAT et al
Group Art Unit	1618
Examiner Name	VU, JAKE MINH
Attorney Docket Number	29195

Sheet	3	of	3
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	52	Satchi-Fainaro et al. "Synthesis and Characterization of A Catalytic Antibody-HPMA Copolymer-Conjugate as A Tool for Tumor Selective Prodrug Activation", Bioorganic & Medicinal Chemistry, 10: 3023-3029, 2002.	
	53	Shabat et al. "In Vivo Activity in A Catalytic Antibody-Prodrug System: Antibody Catalyzed Etoposide Prodrug Activation for Selective Chemotherapy", Proc. Natl. Acad. Sci. USA, 98(13): 7528-7533, 2001.	
	54	Shabat et al. "Multiple Event Activation of A Generic Prodrug Trigger by Antibody Catalysis", Proc. Natl. Acad. Sci. USA, 96: 6925-6930, 1999.	
	55	Stiriba et al. "Dendritic Polymers in Biomedical Applications: From Potential to Clinical Use in Diagnostics and Therapy", Angewandte Chemie, International Edition, 41(8): 1329-1334, 2002.	
	56	Tomalia et al. "Discovery of Dendrimers and Dendritic Polymers: A Brief Historical Perspective", Journal of Polymer Science, Part A: Polymer Chemistry, 40: 2719-2728, 2002.	
	57	Wagner et al. "Efficient Aldolase Catalytic Antibodies That Use the Enamine Mechanism of Natural Enzymes", Science, 270(5243): 1797-1800, 1995.	

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.